NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 641
- Registration Number
- NCT00219193
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00219258
- Locations
- 🇨🇳
Beijing, Beijing, China
An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 157
- Registration Number
- NCT00219245
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1955
- Registration Number
- NCT00219037
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 671
- Registration Number
- NCT00219128
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1125
- Registration Number
- NCT00219154
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 133
- Registration Number
- NCT00219323
- Locations
- 🇯🇵
This study is not being conducted in the United States, Tokyo, Japan
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 839
- Registration Number
- NCT00219089
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Hypertension and Cardiovascular Risk Factors
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00171782
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 718
- Registration Number
- NCT00170755
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath